Let's first become a respected 100m company before thinking about 100bn.
At the moment, they have delivered absolutely nothing for SH return. Most if not all of us are in decent red following 8c (laughable) raise.
Before anyone jumps in and say its biotech and it's long term clearly needs to look at companies who are able to deliver consistent SH value and also deliver a final product...It's isn't either or... it's both
Ann: FSGS Study, Partnering & Commercialisation Investor Briefing, page-101
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
-0.010(2.20%) |
Mkt cap ! $247.9M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 45.8¢ | 43.8¢ | $701.3K | 1.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 111371 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 8072 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |